Money Concepts Capital Corp Sells 3,776 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Money Concepts Capital Corp reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 90,538 shares of the biopharmaceutical company’s stock after selling 3,776 shares during the quarter. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $8,363,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Bellevue Group AG grew its stake in Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after buying an additional 7,093 shares in the last quarter. Quantinno Capital Management LP boosted its position in shares of Gilead Sciences by 149.5% during the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after acquiring an additional 48,910 shares in the last quarter. McAdam LLC raised its position in Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares in the last quarter. IRON Financial LLC bought a new stake in Gilead Sciences during the third quarter worth $830,000. Finally, Capital Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on GILD. Oppenheimer upped their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. Maxim Group downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Piper Sandler upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now owns 80,801 shares in the company, valued at $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 572,824 shares of company stock valued at $53,611,715 in the last 90 days. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Trading Down 0.4 %

NASDAQ GILD opened at $97.99 on Wednesday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $99.45. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The business has a 50 day simple moving average of $92.71 and a 200 day simple moving average of $86.32. The stock has a market capitalization of $122.12 billion, a P/E ratio of 1,088.78, a P/E/G ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.29 EPS. Research analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.